Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.04 and traded as high as $7.87. Cumberland Pharmaceuticals shares last traded at $7.65, with a volume of 69,395 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CPIX. Wall Street Zen lowered Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The stock’s 50 day moving average is $6.83 and its two-hundred day moving average is $5.06. The stock has a market capitalization of $114.60 million, a PE ratio of -10.77 and a beta of 0.08.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%.The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $8.50 million.

Cumberland Pharmaceuticals Dividend Announcement

The company also recently announced a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were paid a dividend of $1.50 per share.

Institutional Trading of Cumberland Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth about $34,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cumberland Pharmaceuticals during the 1st quarter worth about $66,000. Two Sigma Investments LP lifted its stake in Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after purchasing an additional 5,326 shares during the last quarter. Marshall Wace LLP purchased a new stake in Cumberland Pharmaceuticals during the fourth quarter worth approximately $192,000. Finally, Bank of New York Mellon Corp acquired a new position in Cumberland Pharmaceuticals in the second quarter valued at approximately $379,000. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.